<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847145</url>
  </required_header>
  <id_info>
    <org_study_id>V72P13E1</org_study_id>
    <secondary_id>2008-006301-17</secondary_id>
    <nct_id>NCT00847145</nct_id>
  </id_info>
  <brief_title>Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers</brief_title>
  <official_title>A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The proposed study is an Extension Study of V72P13 to Evaluate the Safety, Tolerability and
      Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster
      at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving the Booster Dose of rMenB+OMV NZ Vaccination</measure>
    <time_frame>one month after the booster (fourth) dose</time_frame>
    <description>Immunogenicity was assessed in terms of the percentage of subjects as measured by serum bactericidal antibody titers ≥1:5 the lower limit of the two-sided 95% confidence interval (CI) was ≥75%, directed against N.meningitidis serogroup B reference strains H44/76-SL , NZ98/254, 5/99, one month after the booster (fourth) dose of meningococcal B vaccine with or without the concomitant Measles, Mumps, Rubella, Varicella (MMRV) vaccine in toddlers who were previously vaccinated with three doses of Meningococcal B vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Antibody Response After Receiving the MMRV Vaccination</measure>
    <time_frame>one month after booster (fourth) dose</time_frame>
    <description>Immunogenicity was assessed to demonstrate non-inferiority in terms of percentages of subjects as measured by antibody responses against MMRV vaccine when given concomitantly with the booster (fourth) dose of rMenB+OMV NZ vaccine at 12 months of age when compared to MMRV vaccine when given alone.
The specified cut-off levels for the vaccine antigens : for measles antigen is ≥255mIU/mL, Mumps antigen is ≥10 Enzyme Linked Immunosorbent Assay(ELISA) Antibody(Ab) units, Rubella antigen is ≥10 IU/mL, Varicella antigen is ≥1.25 glycoprotein (gp) ELISA units/ml (seroconversion) and varicella antigen is ≥5 gp ELISA units/ml (seroprotection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Titers After Receiving the Booster Dose of rMenB+OMV NZ Vaccination</measure>
    <time_frame>one month after booster (fourth) vaccination.</time_frame>
    <description>The human serum bactericidal antibody (hSBA) titer responses, one month after receiving booster dose or rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers at 12 Months of Age (Predose 4) After Previously Receiving the Three Doses of rMenB+OMV NZ (Persistence)</measure>
    <time_frame>one month after third vaccination and pre dose fourth (booster) vaccination</time_frame>
    <description>The immunogenicity was assessed as the persistence of bactericidal antibodies at 12 months of age (pre-dose 4) who previously received three doses of rMenB+OMV NZ in the parent study as measured by hSBA GMTs directed against N meningitidis serogroup B reference strains H44/76, NZ98/254 and 5/99.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Previously Receiving the Three Doses of rMenB+OMV NZ Vaccination (Persistence)</measure>
    <time_frame>One month post vaccination and pe-booster (fourth) dose vaccination</time_frame>
    <description>Immunogenicity was assessed to evaluate the persistence in terms of percentages of subjects with hSBA titers ≥ 1:5, previously received three doses of rMenB+OMV NZ directed against N meningitidis serogroup B reference strains H44/76, NZ98/254 and 5/99.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers After Receiving the Booster Dose and Single Dose of rMen+OMV NZ Vaccination (Induction of Immunological Memory)</measure>
    <time_frame>one month after booster (fourth) dose vaccination and pre-fourth dose vaccination</time_frame>
    <description>The immunogenicity was assessed to demonstrate the induction of immunological memory in subjects who were previously received three doses of rMenB+OMV NZ as measured by SBA GMT response in comparison to the fourth dose of rMenB+OMV NZ at 12 months of age ( 12B12M(1a) group) to the response in subjects (12M12B14B 0 who received a single dose of rMenB+OMV NZ vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBA GMTs After a Two-dose Catch-up Schedule or Two-dose Schedule</measure>
    <time_frame>One month after the second dose.</time_frame>
    <description>The immunogenicity of a two-dose catch-up schedule of rMenB+OMV NZ given at 13 and 15 months (12M13B15B) or 12 and 14 months (12M12B14B) to naïve toddlers was assessed by SBA GMTs one month after the second dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With SBA Titers ≥1:5 After a Two-dose Catch-up Schedule or Two-dose Schedule</measure>
    <time_frame>One month after the second dose.</time_frame>
    <description>The immunogenicity of a two-dose catch-up schedule of rMenB+OMV NZ given at 13 and 15 months (12M13B15B) or 12 and 14 months (12M12B14B) to naïve toddlers was assessed as percentages of subjects with SBA titers ≥1:5 one month after the second dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA Geometric Mean Concentration Against Vaccine Antigen 287-953 One Month After the Fourth (Booster) Dose Given at 12 Months</measure>
    <time_frame>One month after the fourth (booster) dose.</time_frame>
    <description>The immune response against vaccine antigen 287-953 was measured by ELISA, one month after the fourth (booster) dose given at 12 months of age (groups 12B12M (1a), 12B13M (1b).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA Geometric Mean Concentration Against Vaccine Antigen 287-953 After Two-dose Catch-up in Toddlers</measure>
    <time_frame>One month after the first dose and one month after the second dose.</time_frame>
    <description>The immune response against vaccine antigen 287-953was measured by ELISA one month after the first dose and one month after the second dose of a two-dose catch-up regimens (12M13B15B and 12M12B14B) in toddlers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Bactericidal Titers ≥ 1:5 (95% CI) Against Strain M10713 One Month After the Fourth (Booster) Dose Given at 12 Months</measure>
    <time_frame>One month after the fourth (booster) dose.</time_frame>
    <description>The immune response was measured as percentages of subjects with SBA ≥ 1:5 (95% CI) against strain M10713, one month after the fourth (booster) dose given at 12 months of age (groups 12B12M (1a), 12B13M (1b).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Reactions During the 7 Days Following rMenB+OMV NZ Vaccination at 12 Months of Age</measure>
    <time_frame>From day 1 to day 7 after each rMenB+OMV NZ vaccination.</time_frame>
    <description>Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 through day 7 after rMenB+OMV NZ vaccination administered at 12 months. For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M and Groups 12B13M (1b) and 12B13M (3b) are combined as Group 12B13M.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Reactions During the 7 Days Following Two-dose Catch-up Schedules of rMenB+OMV NZ Vaccination</measure>
    <time_frame>From day 1 to day 7 after each rMenB+MV NZ vaccination.</time_frame>
    <description>Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 through day 7 after rMenB+OMV NZ vaccination administered with a two-dose catch-up schedules (groups 12M13B15B and 12M12B14B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Reactions During the 7 Days Following MMRV Vaccination at 12 Months of Age</measure>
    <time_frame>From day 1 to day 7 after MMRV vaccination.</time_frame>
    <description>Safety was assessed as the number of subjects who reported solicited local reactions from day 1 through day 7 after the MMRV vaccination concomitantly with rMenB+OMV NZ at 12 months of age (groups 12B12M, 12M12B14B, 12B12M_C) or after MMRV vaccination alone without rMenB+OMV NZ at 12 months (Group 12M13B15B). For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Systemic Reactions During 8-28 Days Following MMRV Vaccination at 12 Months of Age</measure>
    <time_frame>From day 8 to day 28 after MMRV vaccination.</time_frame>
    <description>Safety was assessed as the number of subjects who reported solicited systemic reactions from day 8 through day 28 after the MMRV vaccination concomitantly with rMenB+OMV NZ at 12 months of age (groups 12B12M, 12M12B14B, 12B12M_C) or after MMRV vaccination alone without rMenB+OMV NZ at 12 months (Group 12M13B15B). For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">2249</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>12B12M (1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12B13M (1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12M13B15B (2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12M12B14B (2b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12B12M (3a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12B13M (3b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12B12M_C (4a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12B13M_C (4b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1a - rMenB+OMV NZ and routine vaccines</intervention_name>
    <description>One dose of rMenB vaccine and routine vaccine at study month 12.</description>
    <arm_group_label>12B12M (1a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1b - rMenB+OMV NZ and routine vaccines</intervention_name>
    <description>One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.</description>
    <arm_group_label>12B13M (1b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2a - Routine and rMenB+OMV NZ vaccines</intervention_name>
    <description>One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.</description>
    <arm_group_label>12M13B15B (2a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2b - rMenB+OMV NZ and routine vaccines</intervention_name>
    <description>Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.</description>
    <arm_group_label>12M12B14B (2b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3a - rMenB+OMV NZ and routine vaccines</intervention_name>
    <description>One dose of rMenB vaccine and one dose of routine vaccine at study month 12.</description>
    <arm_group_label>12B12M (3a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations</intervention_name>
    <description>One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.</description>
    <arm_group_label>12B13M (3b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4a- rMenB+OMV NZ and routine vaccines</intervention_name>
    <description>One dose of rMenB vaccine and one dose of routine vaccine at study month 12.</description>
    <arm_group_label>12B12M_C (4a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4b - rMenB+OMV NZ and routine vaccines</intervention_name>
    <description>One dose of rMenB vaccine and one dose of routine vaccine at study month 12.</description>
    <arm_group_label>12B13M_C (4b)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 12-month-old toddlers (0/ +29 days) who completed Study V72P13

        Exclusion Criteria:

          -  Previous ascertained or suspected disease caused by N. meningitidis;

          -  History of severe allergic reaction after previous vaccinations or hypersensitivity to
             any vaccine component;

          -  Any serious chronic or progressive disease

          -  Known or suspected impairment/ alteration of the immune system,

          -  Receipt of, or intent to immunize with another vaccine, within 30 days prior to
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>365 Days</minimum_age>
    <maximum_age>394 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altenburger</name>
      <address>
        <city>Eisenstadt</city>
        <zip>7000</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grässl</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Häckel</name>
      <address>
        <city>Kirchdorf</city>
        <zip>4560</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prieler</name>
      <address>
        <city>Neufeld a.d. Leitha</city>
        <zip>2491</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maurer</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angermayr</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sommer</name>
      <address>
        <city>Wien</city>
        <zip>1230</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Boskovice</city>
        <zip>680 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Brno</city>
        <zip>628 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Chomutov</city>
        <zip>430 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Havlíčkův Brod</city>
        <zip>580 22</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakulta vojenskeho zdravotnictví</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Hranice I-mesto</city>
        <zip>753 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Humpolec</city>
        <zip>396 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Kladno 2</city>
        <zip>272 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Kolín</city>
        <zip>280 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Liberec</city>
        <zip>460 15</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Litomerice</city>
        <zip>412 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 68</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Plzeň</city>
        <zip>305 99</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Rumburk</city>
        <zip>408 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>400 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45</name>
      <address>
        <city>Kotka</city>
        <zip>48600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 46</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 47</name>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 49</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 48</name>
      <address>
        <city>Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 99</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 92</name>
      <address>
        <city>Espelkamp</city>
        <zip>32339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 95</name>
      <address>
        <city>Freising</city>
        <zip>85354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 64</name>
      <address>
        <city>Fulda</city>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 58</name>
      <address>
        <city>Lauffen</city>
        <zip>74348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 57</name>
      <address>
        <city>Marbach a. N.</city>
        <zip>71672</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 80</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 83</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 97</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 96</name>
      <address>
        <city>München</city>
        <zip>81475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 91</name>
      <address>
        <city>Műnchen</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 81</name>
      <address>
        <city>Porta Westfalica</city>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 65</name>
      <address>
        <city>Schwieberdingen</city>
        <zip>71701</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 94</name>
      <address>
        <city>Weilheim</city>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze della Salute</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Messina, Policlinico G. Martino</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena Italia</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatria dell' Ospedale Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Novara</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Igiene e Medicina Preventiva - Università degli Studi di Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL/TA</name>
      <address>
        <city>Taranto</city>
        <zip>74100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>March 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2015</results_first_posted>
  <last_update_submitted>March 2, 2015</last_update_submitted>
  <last_update_submitted_qc>March 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>toddler</keyword>
  <keyword>Meningococcal disease</keyword>
  <keyword>prevention</keyword>
  <keyword>vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 15 sites in Finland, 12 sites in Germany, 5 sites in Austria, 27 sites in Czech Republic and 6 sites in Italy.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>12B12M (1a)</title>
          <description>Previously in the parent study (NCT00657709) subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
        </group>
        <group group_id="P2">
          <title>12B13M (1b)</title>
          <description>Previously in the parent study (NCT00657709) subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
        </group>
        <group group_id="P3">
          <title>12M13B15B (2a)</title>
          <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.</description>
        </group>
        <group group_id="P4">
          <title>12M12B14B (2b)</title>
          <description>Previously in the parent study (NCT00657709) subjects had received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.</description>
        </group>
        <group group_id="P5">
          <title>12B12M (3a)</title>
          <description>Previously in the parent study (NCT00657709) subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
        </group>
        <group group_id="P6">
          <title>12B13M (3b)</title>
          <description>Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.</description>
        </group>
        <group group_id="P7">
          <title>12B12M_C (4a)</title>
          <description>Previously in the parent study (NCT00657709) subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
        </group>
        <group group_id="P8">
          <title>12B13M_C (4b)</title>
          <description>Previously in the parent study (NCT00657709) subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="629"/>
                <participants group_id="P2" count="633"/>
                <participants group_id="P3" count="285"/>
                <participants group_id="P4" count="117"/>
                <participants group_id="P5" count="137"/>
                <participants group_id="P6" count="156"/>
                <participants group_id="P7" count="152"/>
                <participants group_id="P8" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="623"/>
                <participants group_id="P2" count="627"/>
                <participants group_id="P3" count="274"/>
                <participants group_id="P4" count="116"/>
                <participants group_id="P5" count="131"/>
                <participants group_id="P6" count="152"/>
                <participants group_id="P7" count="143"/>
                <participants group_id="P8" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>AE or Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>12B12M (1a)</title>
          <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
        </group>
        <group group_id="B2">
          <title>12B13M (1b)</title>
          <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
        </group>
        <group group_id="B3">
          <title>12M13B15B (2a)</title>
          <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.</description>
        </group>
        <group group_id="B4">
          <title>12M12B14B (2b)</title>
          <description>Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.</description>
        </group>
        <group group_id="B5">
          <title>12B12M (3a)</title>
          <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
        </group>
        <group group_id="B6">
          <title>12B13M (3b)</title>
          <description>Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.</description>
        </group>
        <group group_id="B7">
          <title>12B12M_C (4a)</title>
          <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
        </group>
        <group group_id="B8">
          <title>12B13M_C (4b)</title>
          <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="629"/>
            <count group_id="B2" value="633"/>
            <count group_id="B3" value="285"/>
            <count group_id="B4" value="117"/>
            <count group_id="B5" value="137"/>
            <count group_id="B6" value="156"/>
            <count group_id="B7" value="152"/>
            <count group_id="B8" value="140"/>
            <count group_id="B9" value="2249"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.3" spread="0.5"/>
                    <measurement group_id="B2" value="12.3" spread="0.5"/>
                    <measurement group_id="B3" value="12.3" spread="0.5"/>
                    <measurement group_id="B4" value="12.3" spread="0.5"/>
                    <measurement group_id="B5" value="12.2" spread="0.5"/>
                    <measurement group_id="B6" value="12.2" spread="0.4"/>
                    <measurement group_id="B7" value="12.2" spread="0.5"/>
                    <measurement group_id="B8" value="12.2" spread="0.4"/>
                    <measurement group_id="B9" value="12.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="81"/>
                    <measurement group_id="B7" value="62"/>
                    <measurement group_id="B8" value="73"/>
                    <measurement group_id="B9" value="1097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="62"/>
                    <measurement group_id="B6" value="75"/>
                    <measurement group_id="B7" value="90"/>
                    <measurement group_id="B8" value="67"/>
                    <measurement group_id="B9" value="1152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving the Booster Dose of rMenB+OMV NZ Vaccination</title>
        <description>Immunogenicity was assessed in terms of the percentage of subjects as measured by serum bactericidal antibody titers ≥1:5 the lower limit of the two-sided 95% confidence interval (CI) was ≥75%, directed against N.meningitidis serogroup B reference strains H44/76-SL , NZ98/254, 5/99, one month after the booster (fourth) dose of meningococcal B vaccine with or without the concomitant Measles, Mumps, Rubella, Varicella (MMRV) vaccine in toddlers who were previously vaccinated with three doses of Meningococcal B vaccine.</description>
        <time_frame>one month after the booster (fourth) dose</time_frame>
        <population>The analysis was done on Per Protocol (PP) population – subjects who received all doses of vaccine in parent &amp; present study, provided evaluable serum samples at 1 month after booster dose or 1 month after 2nd dose, blood draw at 1 month after 3rd injection at 6 months in parent &amp; visit 1 blood draw in present study, had no major protocol violation</population>
        <group_list>
          <group group_id="O1">
            <title>12B12M (1a)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12B13M (1b)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving the Booster Dose of rMenB+OMV NZ Vaccination</title>
          <description>Immunogenicity was assessed in terms of the percentage of subjects as measured by serum bactericidal antibody titers ≥1:5 the lower limit of the two-sided 95% confidence interval (CI) was ≥75%, directed against N.meningitidis serogroup B reference strains H44/76-SL , NZ98/254, 5/99, one month after the booster (fourth) dose of meningococcal B vaccine with or without the concomitant Measles, Mumps, Rubella, Varicella (MMRV) vaccine in toddlers who were previously vaccinated with three doses of Meningococcal B vaccine.</description>
          <population>The analysis was done on Per Protocol (PP) population – subjects who received all doses of vaccine in parent &amp; present study, provided evaluable serum samples at 1 month after booster dose or 1 month after 2nd dose, blood draw at 1 month after 3rd injection at 6 months in parent &amp; visit 1 blood draw in present study, had no major protocol violation</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain 44/76-SL (Baseline) (N=211, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="75" upper_limit="86"/>
                    <measurement group_id="O2" value="82" lower_limit="77" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One month after booster (N=210, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 5/99 (Baseline) (N=210, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One month after booster (N=209, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain NZ98/254 (Baseline) (N=211, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O2" value="24" lower_limit="19" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One month after booster (N=211, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="94" lower_limit="90" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Antibody Response After Receiving the MMRV Vaccination</title>
        <description>Immunogenicity was assessed to demonstrate non-inferiority in terms of percentages of subjects as measured by antibody responses against MMRV vaccine when given concomitantly with the booster (fourth) dose of rMenB+OMV NZ vaccine at 12 months of age when compared to MMRV vaccine when given alone.
The specified cut-off levels for the vaccine antigens : for measles antigen is ≥255mIU/mL, Mumps antigen is ≥10 Enzyme Linked Immunosorbent Assay(ELISA) Antibody(Ab) units, Rubella antigen is ≥10 IU/mL, Varicella antigen is ≥1.25 glycoprotein (gp) ELISA units/ml (seroconversion) and varicella antigen is ≥5 gp ELISA units/ml (seroprotection.</description>
        <time_frame>one month after booster (fourth) dose</time_frame>
        <population>This analysis was done on Per Protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>12B12M (1a)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.</description>
          </group>
          <group group_id="O2">
            <title>12M13B15B (2a)</title>
            <description>Previously in the parent study subjects had received only routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ at 13 and 15 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Antibody Response After Receiving the MMRV Vaccination</title>
          <description>Immunogenicity was assessed to demonstrate non-inferiority in terms of percentages of subjects as measured by antibody responses against MMRV vaccine when given concomitantly with the booster (fourth) dose of rMenB+OMV NZ vaccine at 12 months of age when compared to MMRV vaccine when given alone.
The specified cut-off levels for the vaccine antigens : for measles antigen is ≥255mIU/mL, Mumps antigen is ≥10 Enzyme Linked Immunosorbent Assay(ELISA) Antibody(Ab) units, Rubella antigen is ≥10 IU/mL, Varicella antigen is ≥1.25 glycoprotein (gp) ELISA units/ml (seroconversion) and varicella antigen is ≥5 gp ELISA units/ml (seroprotection.</description>
          <population>This analysis was done on Per Protocol (PP) population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Measles strain Schwarz≥255mIU/mLBaselineN=152,147</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after MMRV vaccine (N=151,146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps(strain RIT4385)≥10 U/mL(Baseline)(N=157,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after MMRV vaccine (N=156, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="92" upper_limit="99"/>
                    <measurement group_id="O2" value="96" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella (Wistar RA 27/3) ≥10 (Bas N=163,156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after MMRV vaccine (N=162, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella (Oka, ≥1.25), Bas (N=147,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months after MMRV vaccine (N=146,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella (Oka, ≥5), Bas (N=147,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VarII 2 months after MMRV vaccine (N=146, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="71" upper_limit="85"/>
                    <measurement group_id="O2" value="81" lower_limit="73" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The immunogenicity in 12B12M (1a) group was considered non-inferior to that in group 12M13B15B (2a), if for the measles antigen (two months after the MMRV vaccine), the lower limit of the two-sided 95% CI for the difference in the percentages of subjects with antibody response greater than or equal to the specified cut-off level for Measles antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified cut-off levels for the vaccine antigen measles is ≥255 mIU/mL to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The immunogenicity in 12B12M(1a) group was considered non-inferior to that in group 12M13B15B(2a), if for the mumps antigen (two months after the MMRV vaccine), the lower limit of the two-sided 95% CI for the difference in the percentages of subjects with antibody response greater than or equal to the specified cut-off level for Mumps antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified cut-off level for the vaccine antigen mumps is ≥10 Enzyme Linked Immunosorbent Assay(ELISA) Antibody (Ab) units to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The immunogenicity in 12B12M(1a) group was considered non-inferior to that in group 12M13B15B (2a), if for the rubella antigen(two months after the MMRV vaccine), the lower limit of the two-sided 95% CI for the difference in the percentages of subjects with antibody response greater than or equal to the specified cut-off level for rubella antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified cut-off level for the vaccine antigen rubella is ≥10 IU/mL to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The immunogenicity in 12B12M(1a) group was considered non-inferior to that in group 12M13B15B (2a), if for the varicella antigen (two months after the MMRV vaccine), the lower limit of the two-sided 95% CI for the difference in the percentages of subjects with antibody response greater than or equal to the specified cut-off level for varicella antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified cut-off value for the vaccine antigen varicella is ≥1.25 gpELISA units/mL to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The immunogenicity in 12B12M (1a) group was considered non-inferior to that in group 12M13B15B (2), if for the varicella antigen (two months after the MMRV vaccine), the lower limit of the two-sided 95% CI for the difference in the percentages of the subjects with antibody response greater than or equal to the specified cut-off value for varicella antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The specified cut-off level for the varicella vaccine antigen is ≥5 gp ELISA units/ml (seroprotection) to be greater than -10%.</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Geometric Mean Titers After Receiving the Booster Dose of rMenB+OMV NZ Vaccination</title>
        <description>The human serum bactericidal antibody (hSBA) titer responses, one month after receiving booster dose or rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).</description>
        <time_frame>one month after booster (fourth) vaccination.</time_frame>
        <population>This analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>12B12M (1a)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12B13M (1b)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Titers After Receiving the Booster Dose of rMenB+OMV NZ Vaccination</title>
          <description>The human serum bactericidal antibody (hSBA) titer responses, one month after receiving booster dose or rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).</description>
          <population>This analysis was done on PP population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain 44/76-SL (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.27" upper_limit="12"/>
                    <measurement group_id="O2" value="10" lower_limit="9.11" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after booster (N=210, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" lower_limit="123" upper_limit="156"/>
                    <measurement group_id="O2" value="119" lower_limit="105" upper_limit="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 5/99 (N=210, 213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="71" upper_limit="93"/>
                    <measurement group_id="O2" value="81" lower_limit="71" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after booster (N=209, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1503" lower_limit="1339" upper_limit="1686"/>
                    <measurement group_id="O2" value="1429" lower_limit="1274" upper_limit="1603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain NZ98/254 (N=211, 215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="1.8" upper_limit="2.38"/>
                    <measurement group_id="O2" value="2.21" lower_limit="1.92" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after booster (N=211,213)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="33" upper_limit="46"/>
                    <measurement group_id="O2" value="32" lower_limit="27" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers at 12 Months of Age (Predose 4) After Previously Receiving the Three Doses of rMenB+OMV NZ (Persistence)</title>
        <description>The immunogenicity was assessed as the persistence of bactericidal antibodies at 12 months of age (pre-dose 4) who previously received three doses of rMenB+OMV NZ in the parent study as measured by hSBA GMTs directed against N meningitidis serogroup B reference strains H44/76, NZ98/254 and 5/99.</description>
        <time_frame>one month after third vaccination and pre dose fourth (booster) vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>12B12M (1a)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjets received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine</description>
          </group>
          <group group_id="O2">
            <title>12B13M (1b)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Men246</title>
            <description>Combined groups of 1a and 1b who previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months of age and one dose of MMRV vaccine at 12 months (1a group) and at 13 months of age (1b) group in the present study.</description>
          </group>
          <group group_id="O4">
            <title>Routine246</title>
            <description>Combined groups of 12M13B15B (2a) and 12M12B14B (2b) who previously received routine vaccine at 2, 4 an 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 13 and 15 months of age [12M13B15B (2a)]; 12 and 14 months [12M12B14B (2b)] in the parent study and one dose of MMRV vaccine at 12 months of age in both the groups in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers at 12 Months of Age (Predose 4) After Previously Receiving the Three Doses of rMenB+OMV NZ (Persistence)</title>
          <description>The immunogenicity was assessed as the persistence of bactericidal antibodies at 12 months of age (pre-dose 4) who previously received three doses of rMenB+OMV NZ in the parent study as measured by hSBA GMTs directed against N meningitidis serogroup B reference strains H44/76, NZ98/254 and 5/99.</description>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="272"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain 44/76-SL (Baseline) N=134, 131, 265,49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.05" upper_limit="1.27"/>
                    <measurement group_id="O2" value="1.15" lower_limit="1.05" upper_limit="1.27"/>
                    <measurement group_id="O3" value="1.15" lower_limit="1.08" upper_limit="1.24"/>
                    <measurement group_id="O4" value="1.14" lower_limit="0.99" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 3rd vac.in parent study N=139,133,272,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="81" upper_limit="104"/>
                    <measurement group_id="O2" value="83" lower_limit="73" upper_limit="94"/>
                    <measurement group_id="O3" value="87" lower_limit="79" upper_limit="95"/>
                    <measurement group_id="O4" value="1.19" lower_limit="1.07" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Boodster vac.in present study N=139,133,272,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9" upper_limit="12"/>
                    <measurement group_id="O2" value="10" lower_limit="8.7" upper_limit="12"/>
                    <measurement group_id="O3" value="10" lower_limit="9.28" upper_limit="12"/>
                    <measurement group_id="O4" value="1.08" lower_limit="0.99" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 5/99 (Baseline) N=132,129,261,49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="1.01" upper_limit="1.26"/>
                    <measurement group_id="O2" value="1.24" lower_limit="1.11" upper_limit="1.39"/>
                    <measurement group_id="O3" value="1.18" lower_limit="1.09" upper_limit="1.28"/>
                    <measurement group_id="O4" value="1.11" lower_limit="1.01" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1M after 3rd vac. in parent study N=139,133,272,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="615" lower_limit="538" upper_limit="704"/>
                    <measurement group_id="O2" value="620" lower_limit="540" upper_limit="712"/>
                    <measurement group_id="O3" value="617" lower_limit="560" upper_limit="680"/>
                    <measurement group_id="O4" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Booster vac.in present study N=139,133,272,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="72" upper_limit="100"/>
                    <measurement group_id="O2" value="79" lower_limit="67" upper_limit="94"/>
                    <measurement group_id="O3" value="82" lower_limit="73" upper_limit="92"/>
                    <measurement group_id="O4" value="1.03" lower_limit="0.97" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain NZ98/254 (Baseline) N=135,130,265,49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.98" upper_limit="1.13"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.04" upper_limit="1.21"/>
                    <measurement group_id="O3" value="1.09" lower_limit="1.03" upper_limit="1.15"/>
                    <measurement group_id="O4" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1M after 3rd vac. in parent study.N=139,132,271,52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O2" value="14" lower_limit="12" upper_limit="17"/>
                    <measurement group_id="O3" value="13" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O4" value="1.07" lower_limit="0.94" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-booster vac in present study. N=139,132,271,52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.72" upper_limit="2.43"/>
                    <measurement group_id="O2" value="2.02" lower_limit="1.69" upper_limit="2.42"/>
                    <measurement group_id="O3" value="2.03" lower_limit="1.79" upper_limit="2.3"/>
                    <measurement group_id="O4" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Previously Receiving the Three Doses of rMenB+OMV NZ Vaccination (Persistence)</title>
        <description>Immunogenicity was assessed to evaluate the persistence in terms of percentages of subjects with hSBA titers ≥ 1:5, previously received three doses of rMenB+OMV NZ directed against N meningitidis serogroup B reference strains H44/76, NZ98/254 and 5/99.</description>
        <time_frame>One month post vaccination and pe-booster (fourth) dose vaccination</time_frame>
        <population>The analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>12B12M (1a)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjets received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine</description>
          </group>
          <group group_id="O2">
            <title>12B13M (1b)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Men246</title>
            <description>Combined groups of 1a and 1b who previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months of age and one dose of MMRV vaccine at 12 months (1a group) and at 13 months of age (1b) group in the present study.</description>
          </group>
          <group group_id="O4">
            <title>Routine246</title>
            <description>Combined groups of 12M13B15B (2a) and 12M12B14B (2b) who previously received routine vaccine at 2, 4 an 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 13 and 15 months of age [12M13B15B (2a)]; 12 and 14 months [12M12B14B (2b)] in the parent study and one dose of MMRV vaccine at 12 months of age in both the groups in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Previously Receiving the Three Doses of rMenB+OMV NZ Vaccination (Persistence)</title>
          <description>Immunogenicity was assessed to evaluate the persistence in terms of percentages of subjects with hSBA titers ≥ 1:5, previously received three doses of rMenB+OMV NZ directed against N meningitidis serogroup B reference strains H44/76, NZ98/254 and 5/99.</description>
          <population>The analysis was done on PP population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="272"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL Baseline in present studyN=134,131,265,49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O4" value="4" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 3rd vac in parent study.N=139,133,272,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-booster vac. in present study.N=139,133,272,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="73" upper_limit="87"/>
                    <measurement group_id="O2" value="82" lower_limit="74" upper_limit="88"/>
                    <measurement group_id="O3" value="81" lower_limit="76" upper_limit="86"/>
                    <measurement group_id="O4" value="2" lower_limit="0.05" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 Baseline in parent study N=132,129,261,49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O4" value="2" lower_limit="0.052" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1M after 3rd vac in parent study N=139,133,272,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Boostervac.in present study N=139,133,272,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 Baseline in parent study N=135,130,265,49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.019" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O3" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 3rd vac. in parent studyN=139,132,271,52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="74" upper_limit="87"/>
                    <measurement group_id="O2" value="85" lower_limit="78" upper_limit="90"/>
                    <measurement group_id="O3" value="83" lower_limit="78" upper_limit="87"/>
                    <measurement group_id="O4" value="2" lower_limit="0.049" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Booster vac in present study N=139,132,271,52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="14" upper_limit="29"/>
                    <measurement group_id="O2" value="20" lower_limit="13" upper_limit="28"/>
                    <measurement group_id="O3" value="20" lower_limit="16" upper_limit="26"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers After Receiving the Booster Dose and Single Dose of rMen+OMV NZ Vaccination (Induction of Immunological Memory)</title>
        <description>The immunogenicity was assessed to demonstrate the induction of immunological memory in subjects who were previously received three doses of rMenB+OMV NZ as measured by SBA GMT response in comparison to the fourth dose of rMenB+OMV NZ at 12 months of age ( 12B12M(1a) group) to the response in subjects (12M12B14B 0 who received a single dose of rMenB+OMV NZ vaccine.</description>
        <time_frame>one month after booster (fourth) dose vaccination and pre-fourth dose vaccination</time_frame>
        <population>This analysis was done on the PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>12B12M (1a)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine</description>
          </group>
          <group group_id="O2">
            <title>12M12B14B (2b)</title>
            <description>Previously in the parent study subjects had received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine was given concomitantly at 12 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers After Receiving the Booster Dose and Single Dose of rMen+OMV NZ Vaccination (Induction of Immunological Memory)</title>
          <description>The immunogenicity was assessed to demonstrate the induction of immunological memory in subjects who were previously received three doses of rMenB+OMV NZ as measured by SBA GMT response in comparison to the fourth dose of rMenB+OMV NZ at 12 months of age ( 12B12M(1a) group) to the response in subjects (12M12B14B 0 who received a single dose of rMenB+OMV NZ vaccine.</description>
          <population>This analysis was done on the PP population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>44/76-SL (Baseline) (N=211, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.32" upper_limit="12"/>
                    <measurement group_id="O2" value="1.18" lower_limit="0.96" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after Booster or 1st rMenB (N=210, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" lower_limit="123" upper_limit="159"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (Baseline) (N=210, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="73" upper_limit="93"/>
                    <measurement group_id="O2" value="1" lower_limit="0.81" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after Booster or 1sr rMenB (N=209, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1538" lower_limit="1337" upper_limit="1769"/>
                    <measurement group_id="O2" value="58" lower_limit="46" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (Baseline) (N=211, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" lower_limit="1.83" upper_limit="2.31"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.84" upper_limit="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1M after Booster or 1st rMenB (N=211, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="34" upper_limit="46"/>
                    <measurement group_id="O2" value="4.18" lower_limit="3.18" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBA GMTs After a Two-dose Catch-up Schedule or Two-dose Schedule</title>
        <description>The immunogenicity of a two-dose catch-up schedule of rMenB+OMV NZ given at 13 and 15 months (12M13B15B) or 12 and 14 months (12M12B14B) to naïve toddlers was assessed by SBA GMTs one month after the second dose.</description>
        <time_frame>One month after the second dose.</time_frame>
        <population>The analysis was done on the SBA PP Catch-up population.</population>
        <group_list>
          <group group_id="O1">
            <title>12M13B15B (2a)</title>
            <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12M12B14B (2b)</title>
            <description>Previously in the parent study subjects had received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>SBA GMTs After a Two-dose Catch-up Schedule or Two-dose Schedule</title>
          <description>The immunogenicity of a two-dose catch-up schedule of rMenB+OMV NZ given at 13 and 15 months (12M13B15B) or 12 and 14 months (12M12B14B) to naïve toddlers was assessed by SBA GMTs one month after the second dose.</description>
          <population>The analysis was done on the SBA PP Catch-up population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain H44/76, Baseline (N=161,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="1.15" upper_limit="1.35"/>
                    <measurement group_id="O2" value="1.22" lower_limit="1.07" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 2nd Vac. (N=163, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271" lower_limit="237" upper_limit="310"/>
                    <measurement group_id="O2" value="248" lower_limit="201" upper_limit="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 5/99, Baseline (N=160, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="1" upper_limit="1.13"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.94" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 2nd Vac. (N=164, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599" lower_limit="520" upper_limit="690"/>
                    <measurement group_id="O2" value="627" lower_limit="502" upper_limit="783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain NZ98/254, Baseline (N=162, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.98" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.97" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1M after 2nd Vac. (N=164, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="38" upper_limit="49"/>
                    <measurement group_id="O2" value="32" lower_limit="26" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With SBA Titers ≥1:5 After a Two-dose Catch-up Schedule or Two-dose Schedule</title>
        <description>The immunogenicity of a two-dose catch-up schedule of rMenB+OMV NZ given at 13 and 15 months (12M13B15B) or 12 and 14 months (12M12B14B) to naïve toddlers was assessed as percentages of subjects with SBA titers ≥1:5 one month after the second dose.</description>
        <time_frame>One month after the second dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>12M13B15B (2a)</title>
            <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12M12B14B (2b)</title>
            <description>Previously in the parent study subjects had received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With SBA Titers ≥1:5 After a Two-dose Catch-up Schedule or Two-dose Schedule</title>
          <description>The immunogenicity of a two-dose catch-up schedule of rMenB+OMV NZ given at 13 and 15 months (12M13B15B) or 12 and 14 months (12M12B14B) to naïve toddlers was assessed as percentages of subjects with SBA titers ≥1:5 one month after the second dose.</description>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain H44/76, Baseline (N=161,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 2nd Vac. (N=163, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 5/99, Baseline (N=160, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="1" lower_limit="0.038" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 2nd Vac. (N=164, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain NZ98/254, Baseline (N=162, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.016" upper_limit="3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1M after 2nd Vac. (N=164, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="96" lower_limit="88" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA Geometric Mean Concentration Against Vaccine Antigen 287-953 One Month After the Fourth (Booster) Dose Given at 12 Months</title>
        <description>The immune response against vaccine antigen 287-953 was measured by ELISA, one month after the fourth (booster) dose given at 12 months of age (groups 12B12M (1a), 12B13M (1b).</description>
        <time_frame>One month after the fourth (booster) dose.</time_frame>
        <population>The analysis was done on the SBA PP Booster population.</population>
        <group_list>
          <group group_id="O1">
            <title>12B12M (1a)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12B13M (1b)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA Geometric Mean Concentration Against Vaccine Antigen 287-953 One Month After the Fourth (Booster) Dose Given at 12 Months</title>
          <description>The immune response against vaccine antigen 287-953 was measured by ELISA, one month after the fourth (booster) dose given at 12 months of age (groups 12B12M (1a), 12B13M (1b).</description>
          <population>The analysis was done on the SBA PP Booster population.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=212,216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390" lower_limit="351" upper_limit="433"/>
                    <measurement group_id="O2" value="389" lower_limit="349" upper_limit="434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after Booster (N=213, 214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6225" lower_limit="5571" upper_limit="6956"/>
                    <measurement group_id="O2" value="5608" lower_limit="5111" upper_limit="6154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA Geometric Mean Concentration Against Vaccine Antigen 287-953 After Two-dose Catch-up in Toddlers</title>
        <description>The immune response against vaccine antigen 287-953was measured by ELISA one month after the first dose and one month after the second dose of a two-dose catch-up regimens (12M13B15B and 12M12B14B) in toddlers.</description>
        <time_frame>One month after the first dose and one month after the second dose.</time_frame>
        <population>The analysis was done on the SBA PP Catch-up population.</population>
        <group_list>
          <group group_id="O1">
            <title>12M13B15B (2a)</title>
            <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12M12B14B (2b)</title>
            <description>Previously in the parent study subjects had received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA Geometric Mean Concentration Against Vaccine Antigen 287-953 After Two-dose Catch-up in Toddlers</title>
          <description>The immune response against vaccine antigen 287-953was measured by ELISA one month after the first dose and one month after the second dose of a two-dose catch-up regimens (12M13B15B and 12M12B14B) in toddlers.</description>
          <population>The analysis was done on the SBA PP Catch-up population.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=162,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="20" upper_limit="21"/>
                    <measurement group_id="O2" value="22" lower_limit="19" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 1st Vac. (N=162,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" lower_limit="95" upper_limit="136"/>
                    <measurement group_id="O2" value="120" lower_limit="88" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 M after 2nd Vac.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5698" lower_limit="5030" upper_limit="6454"/>
                    <measurement group_id="O2" value="7154" lower_limit="5880" upper_limit="8704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Bactericidal Titers ≥ 1:5 (95% CI) Against Strain M10713 One Month After the Fourth (Booster) Dose Given at 12 Months</title>
        <description>The immune response was measured as percentages of subjects with SBA ≥ 1:5 (95% CI) against strain M10713, one month after the fourth (booster) dose given at 12 months of age (groups 12B12M (1a), 12B13M (1b).</description>
        <time_frame>One month after the fourth (booster) dose.</time_frame>
        <population>The analysis was done on the SBA PP Booster population.</population>
        <group_list>
          <group group_id="O1">
            <title>12B12M (1a)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12B13M (1b)</title>
            <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Bactericidal Titers ≥ 1:5 (95% CI) Against Strain M10713 One Month After the Fourth (Booster) Dose Given at 12 Months</title>
          <description>The immune response was measured as percentages of subjects with SBA ≥ 1:5 (95% CI) against strain M10713, one month after the fourth (booster) dose given at 12 months of age (groups 12B12M (1a), 12B13M (1b).</description>
          <population>The analysis was done on the SBA PP Booster population.</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Booster Vac.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="60" upper_limit="97"/>
                    <measurement group_id="O2" value="59" lower_limit="39" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month After Booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Reactions During the 7 Days Following rMenB+OMV NZ Vaccination at 12 Months of Age</title>
        <description>Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 through day 7 after rMenB+OMV NZ vaccination administered at 12 months. For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M and Groups 12B13M (1b) and 12B13M (3b) are combined as Group 12B13M.</description>
        <time_frame>From day 1 to day 7 after each rMenB+OMV NZ vaccination.</time_frame>
        <population>Analysis performed on the Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>12B12M_C (4a)</title>
            <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12B13M_C (4b)</title>
            <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>12B12M</title>
            <description>Combination of Groups 12B12M (1a) and 12B12M (3a).</description>
          </group>
          <group group_id="O4">
            <title>12B13M</title>
            <description>Combination of Groups 12B13M (1b) and 12B13M (3b).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Reactions During the 7 Days Following rMenB+OMV NZ Vaccination at 12 Months of Age</title>
          <description>Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 through day 7 after rMenB+OMV NZ vaccination administered at 12 months. For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M and Groups 12B13M (1b) and 12B13M (3b) are combined as Group 12B13M.</description>
          <population>Analysis performed on the Safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="765"/>
                <count group_id="O4" value="789"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="639"/>
                    <measurement group_id="O4" value="673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="546"/>
                    <measurement group_id="O4" value="563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="504"/>
                    <measurement group_id="O4" value="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="388"/>
                    <measurement group_id="O4" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="284"/>
                    <measurement group_id="O4" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="695"/>
                    <measurement group_id="O4" value="671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="312"/>
                    <measurement group_id="O4" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="362"/>
                    <measurement group_id="O4" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="188"/>
                    <measurement group_id="O4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="560"/>
                    <measurement group_id="O4" value="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="327"/>
                    <measurement group_id="O4" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Oth.to Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Urt.to Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Oth.to Doc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Urt.to Doc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Par.to Doc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Sal.to Doc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med. Att. Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="356"/>
                    <measurement group_id="O4" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic Med. Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="436"/>
                    <measurement group_id="O4" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Reactions During the 7 Days Following Two-dose Catch-up Schedules of rMenB+OMV NZ Vaccination</title>
        <description>Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 through day 7 after rMenB+OMV NZ vaccination administered with a two-dose catch-up schedules (groups 12M13B15B and 12M12B14B).</description>
        <time_frame>From day 1 to day 7 after each rMenB+MV NZ vaccination.</time_frame>
        <population>Analysis performed on the Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>12M13B15B (2a)</title>
            <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>12M12B14B (2b)</title>
            <description>Previously in the parent study subjects had received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Reactions During the 7 Days Following Two-dose Catch-up Schedules of rMenB+OMV NZ Vaccination</title>
          <description>Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 through day 7 after rMenB+OMV NZ vaccination administered with a two-dose catch-up schedules (groups 12M13B15B and 12M12B14B).</description>
          <population>Analysis performed on the Safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Tenderness (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Tenderness (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Erythema (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Erythema (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Induration (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Induration (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Swelling (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MenB Swelling (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Oth.to Fever (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Oth.to Fever (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Urt.to Fever (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Urt.to Fever (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Oth.to Doc. (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Oth.to Doc. (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Urt.to Doc. (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Urt.to Doc. (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Swelling (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Swelling (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Par.to Doc. (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Par.to Doc. (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Sal.to Doc. (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Sal.to Doc. (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med. Att. Fever (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med. Att. Fever (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38C) (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38C) (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used (1st vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic Med. Used (2nd vacc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Reactions During the 7 Days Following MMRV Vaccination at 12 Months of Age</title>
        <description>Safety was assessed as the number of subjects who reported solicited local reactions from day 1 through day 7 after the MMRV vaccination concomitantly with rMenB+OMV NZ at 12 months of age (groups 12B12M, 12M12B14B, 12B12M_C) or after MMRV vaccination alone without rMenB+OMV NZ at 12 months (Group 12M13B15B). For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M.</description>
        <time_frame>From day 1 to day 7 after MMRV vaccination.</time_frame>
        <population>Analysis performed on the Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>12M13B15B (2a)</title>
            <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
2a - Routine and rMenB+OMV NZ vaccines: One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.</description>
          </group>
          <group group_id="O2">
            <title>12M12B14B (2b)</title>
            <description>Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
2b - rMenB+OMV NZ and routine vaccines: Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.</description>
          </group>
          <group group_id="O3">
            <title>12B12M_C (4a)</title>
            <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
4a- rMenB+OMV NZ and routine vaccines: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.</description>
          </group>
          <group group_id="O4">
            <title>12B12M</title>
            <description>Combination of Groups 12B12M (1a) and 12B12M (3a).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local Reactions During the 7 Days Following MMRV Vaccination at 12 Months of Age</title>
          <description>Safety was assessed as the number of subjects who reported solicited local reactions from day 1 through day 7 after the MMRV vaccination concomitantly with rMenB+OMV NZ at 12 months of age (groups 12B12M, 12M12B14B, 12B12M_C) or after MMRV vaccination alone without rMenB+OMV NZ at 12 months (Group 12M13B15B). For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M.</description>
          <population>Analysis performed on the Safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="760"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMRV Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMRV Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMRV Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMRV Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Systemic Reactions During 8-28 Days Following MMRV Vaccination at 12 Months of Age</title>
        <description>Safety was assessed as the number of subjects who reported solicited systemic reactions from day 8 through day 28 after the MMRV vaccination concomitantly with rMenB+OMV NZ at 12 months of age (groups 12B12M, 12M12B14B, 12B12M_C) or after MMRV vaccination alone without rMenB+OMV NZ at 12 months (Group 12M13B15B). For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M.</description>
        <time_frame>From day 8 to day 28 after MMRV vaccination.</time_frame>
        <population>Analysis performed on the Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>12M13B15B (2a)</title>
            <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
2a - Routine and rMenB+OMV NZ vaccines: One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.</description>
          </group>
          <group group_id="O2">
            <title>12M12B14B (2b)</title>
            <description>Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
2b - rMenB+OMV NZ and routine vaccines: Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.</description>
          </group>
          <group group_id="O3">
            <title>12B12M_C (4a)</title>
            <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
4a- rMenB+OMV NZ and routine vaccines: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.</description>
          </group>
          <group group_id="O4">
            <title>12B12M</title>
            <description>Combination of Groups 12B12M (1a) and 12B12M (3a).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Systemic Reactions During 8-28 Days Following MMRV Vaccination at 12 Months of Age</title>
          <description>Safety was assessed as the number of subjects who reported solicited systemic reactions from day 8 through day 28 after the MMRV vaccination concomitantly with rMenB+OMV NZ at 12 months of age (groups 12B12M, 12M12B14B, 12B12M_C) or after MMRV vaccination alone without rMenB+OMV NZ at 12 months (Group 12M13B15B). For the safety analysis purpose, Groups 12B12M (1a) and 12B12M (3a) are combined as Group 12B12M.</description>
          <population>Analysis performed on the Safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="760"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Oth.to Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Urt.to Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Oth.to Doc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash Urt.to Doc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Par.to Doc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gland Sal.to Doc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med. Att. Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic Med. Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All solicited and unsolicited Adverse Events (AEs) were collected from Day 1 to 7; serious AEs (SAEs), possibly or probably related, unrelated , medically attended and leading to premature withdrawal AEs were collected during the overall study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>12B12M</title>
          <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
This group is a combination of Groups 12B12M (1a) and 12B12M (3a) for safety data analysis purposes.</description>
        </group>
        <group group_id="E2">
          <title>12B13M</title>
          <description>Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
This group is a combination of Groups 12B13M (1b) and 12B13M (3b) for safety data analysis purposes.</description>
        </group>
        <group group_id="E3">
          <title>12M13B15B (2a)</title>
          <description>Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
2a - Routine and rMenB+OMV NZ vaccines: One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.</description>
        </group>
        <group group_id="E4">
          <title>12M12B14B (2b)</title>
          <description>Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
2b - rMenB+OMV NZ and routine vaccines: Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.</description>
        </group>
        <group group_id="E5">
          <title>12B12M_C (4a)</title>
          <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
4a- rMenB+OMV NZ and routine vaccines: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.</description>
        </group>
        <group group_id="E6">
          <title>12B13M_C (4b)</title>
          <description>Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
4b - rMenB+OMV NZ and routine vaccines: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="789"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="284"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="117"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="765"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="789"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="789"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="789"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Growth retardation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Strabismus correction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="789"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="789"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="754" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="760" subjects_at_risk="789"/>
                <counts group_id="E3" subjects_affected="282" subjects_at_risk="284"/>
                <counts group_id="E4" subjects_affected="116" subjects_at_risk="117"/>
                <counts group_id="E5" subjects_affected="145" subjects_at_risk="152"/>
                <counts group_id="E6" subjects_affected="132" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="48" subjects_affected="29" subjects_at_risk="765"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="789"/>
                <counts group_id="E3" events="24" subjects_affected="13" subjects_at_risk="284"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E5" events="14" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="342" subjects_affected="194" subjects_at_risk="765"/>
                <counts group_id="E2" events="268" subjects_affected="171" subjects_at_risk="789"/>
                <counts group_id="E3" events="215" subjects_affected="92" subjects_at_risk="284"/>
                <counts group_id="E4" events="101" subjects_affected="48" subjects_at_risk="117"/>
                <counts group_id="E5" events="57" subjects_affected="31" subjects_at_risk="152"/>
                <counts group_id="E6" events="38" subjects_affected="25" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="765"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="789"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="284"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="78" subjects_affected="56" subjects_at_risk="765"/>
                <counts group_id="E2" events="53" subjects_affected="39" subjects_at_risk="789"/>
                <counts group_id="E3" events="52" subjects_affected="38" subjects_at_risk="284"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E6" events="21" subjects_affected="11" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="558" subjects_affected="327" subjects_at_risk="765"/>
                <counts group_id="E2" events="467" subjects_affected="294" subjects_at_risk="789"/>
                <counts group_id="E3" events="302" subjects_affected="132" subjects_at_risk="284"/>
                <counts group_id="E4" events="140" subjects_affected="59" subjects_at_risk="117"/>
                <counts group_id="E5" events="86" subjects_affected="48" subjects_at_risk="152"/>
                <counts group_id="E6" events="83" subjects_affected="50" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1891" subjects_affected="549" subjects_at_risk="765"/>
                <counts group_id="E2" events="1326" subjects_affected="539" subjects_at_risk="789"/>
                <counts group_id="E3" events="1018" subjects_affected="213" subjects_at_risk="284"/>
                <counts group_id="E4" events="476" subjects_affected="94" subjects_at_risk="117"/>
                <counts group_id="E5" events="316" subjects_affected="92" subjects_at_risk="152"/>
                <counts group_id="E6" events="179" subjects_affected="82" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="1392" subjects_affected="419" subjects_at_risk="765"/>
                <counts group_id="E2" events="1188" subjects_affected="424" subjects_at_risk="789"/>
                <counts group_id="E3" events="717" subjects_affected="165" subjects_at_risk="284"/>
                <counts group_id="E4" events="325" subjects_affected="78" subjects_at_risk="117"/>
                <counts group_id="E5" events="223" subjects_affected="67" subjects_at_risk="152"/>
                <counts group_id="E6" events="159" subjects_affected="62" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1648" subjects_affected="561" subjects_at_risk="765"/>
                <counts group_id="E2" events="1107" subjects_affected="563" subjects_at_risk="789"/>
                <counts group_id="E3" events="759" subjects_affected="224" subjects_at_risk="284"/>
                <counts group_id="E4" events="377" subjects_affected="89" subjects_at_risk="117"/>
                <counts group_id="E5" events="329" subjects_affected="104" subjects_at_risk="152"/>
                <counts group_id="E6" events="165" subjects_affected="81" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="874" subjects_affected="320" subjects_at_risk="765"/>
                <counts group_id="E2" events="667" subjects_affected="287" subjects_at_risk="789"/>
                <counts group_id="E3" events="418" subjects_affected="127" subjects_at_risk="284"/>
                <counts group_id="E4" events="177" subjects_affected="53" subjects_at_risk="117"/>
                <counts group_id="E5" events="166" subjects_affected="54" subjects_at_risk="152"/>
                <counts group_id="E6" events="94" subjects_affected="40" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1136" subjects_affected="511" subjects_at_risk="765"/>
                <counts group_id="E2" events="560" subjects_affected="356" subjects_at_risk="789"/>
                <counts group_id="E3" events="584" subjects_affected="208" subjects_at_risk="284"/>
                <counts group_id="E4" events="211" subjects_affected="85" subjects_at_risk="117"/>
                <counts group_id="E5" events="256" subjects_affected="110" subjects_at_risk="152"/>
                <counts group_id="E6" events="125" subjects_affected="80" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="72" subjects_affected="60" subjects_at_risk="765"/>
                <counts group_id="E2" events="78" subjects_affected="62" subjects_at_risk="789"/>
                <counts group_id="E3" events="45" subjects_affected="38" subjects_at_risk="284"/>
                <counts group_id="E4" events="16" subjects_affected="13" subjects_at_risk="117"/>
                <counts group_id="E5" events="20" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E6" events="9" subjects_affected="6" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="57" subjects_affected="46" subjects_at_risk="765"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="789"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="284"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="60" subjects_affected="49" subjects_at_risk="765"/>
                <counts group_id="E2" events="100" subjects_affected="59" subjects_at_risk="789"/>
                <counts group_id="E3" events="37" subjects_affected="20" subjects_at_risk="284"/>
                <counts group_id="E4" events="19" subjects_affected="14" subjects_at_risk="117"/>
                <counts group_id="E5" events="18" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E6" events="9" subjects_affected="6" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="765"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="789"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="284"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="765"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="789"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="284"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="765"/>
                <counts group_id="E2" events="29" subjects_affected="27" subjects_at_risk="789"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="284"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="62" subjects_affected="49" subjects_at_risk="765"/>
                <counts group_id="E2" events="81" subjects_affected="62" subjects_at_risk="789"/>
                <counts group_id="E3" events="48" subjects_affected="37" subjects_at_risk="284"/>
                <counts group_id="E4" events="28" subjects_affected="19" subjects_at_risk="117"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="121" subjects_affected="80" subjects_at_risk="765"/>
                <counts group_id="E2" events="133" subjects_affected="79" subjects_at_risk="789"/>
                <counts group_id="E3" events="56" subjects_affected="42" subjects_at_risk="284"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="38" subjects_at_risk="765"/>
                <counts group_id="E2" events="64" subjects_affected="54" subjects_at_risk="789"/>
                <counts group_id="E3" events="21" subjects_affected="19" subjects_at_risk="284"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="765"/>
                <counts group_id="E2" events="43" subjects_affected="38" subjects_at_risk="789"/>
                <counts group_id="E3" events="35" subjects_affected="26" subjects_at_risk="284"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="83" subjects_affected="67" subjects_at_risk="765"/>
                <counts group_id="E2" events="71" subjects_affected="59" subjects_at_risk="789"/>
                <counts group_id="E3" events="66" subjects_affected="51" subjects_at_risk="284"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="117"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="765"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="789"/>
                <counts group_id="E3" events="29" subjects_affected="23" subjects_at_risk="284"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="599" subjects_affected="362" subjects_at_risk="765"/>
                <counts group_id="E2" events="569" subjects_affected="355" subjects_at_risk="789"/>
                <counts group_id="E3" events="430" subjects_affected="178" subjects_at_risk="284"/>
                <counts group_id="E4" events="154" subjects_affected="70" subjects_at_risk="117"/>
                <counts group_id="E5" events="99" subjects_affected="64" subjects_at_risk="152"/>
                <counts group_id="E6" events="91" subjects_affected="61" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1121" subjects_affected="562" subjects_at_risk="765"/>
                <counts group_id="E2" events="996" subjects_affected="540" subjects_at_risk="789"/>
                <counts group_id="E3" events="742" subjects_affected="226" subjects_at_risk="284"/>
                <counts group_id="E4" events="300" subjects_affected="95" subjects_at_risk="117"/>
                <counts group_id="E5" events="199" subjects_affected="89" subjects_at_risk="152"/>
                <counts group_id="E6" events="142" subjects_affected="76" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" events="630" subjects_affected="313" subjects_at_risk="765"/>
                <counts group_id="E2" events="582" subjects_affected="318" subjects_at_risk="789"/>
                <counts group_id="E3" events="444" subjects_affected="156" subjects_at_risk="284"/>
                <counts group_id="E4" events="152" subjects_affected="63" subjects_at_risk="117"/>
                <counts group_id="E5" events="117" subjects_affected="61" subjects_at_risk="152"/>
                <counts group_id="E6" events="84" subjects_affected="45" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="45" subjects_affected="33" subjects_at_risk="765"/>
                <counts group_id="E2" events="51" subjects_affected="46" subjects_at_risk="789"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="284"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E5" events="15" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E6" events="14" subjects_affected="11" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="310" subjects_affected="178" subjects_at_risk="765"/>
                <counts group_id="E2" events="104" subjects_affected="65" subjects_at_risk="789"/>
                <counts group_id="E3" events="141" subjects_affected="78" subjects_at_risk="284"/>
                <counts group_id="E4" events="61" subjects_affected="30" subjects_at_risk="117"/>
                <counts group_id="E5" events="46" subjects_affected="22" subjects_at_risk="152"/>
                <counts group_id="E6" events="13" subjects_affected="9" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

